Hoth Therapeutics Inc (HOTH) Quote

HOTH...................................................https://stockcharts.com/h-sc/ui?s=HOTH&p=W&b=5&g=0&id=p86431144783

🔥 Big Wins for $HOTH in Cancer Research! 🔥

✅ HT-001 (Phase 2a Trial): 100% success rate in reducing skin toxicities from cancer treatments! A major step in improving patient quality of life.
📄 Read more: https://ir.hoththerapeutics.com/

✅ HT-KIT (Preclinical Study): Effectively inhibited tumor growth, showing strong potential as a future cancer therapy.
📄 Details: prnewswire.com

🚀 Hoth Therapeutics is making bold moves in biotech! Keep an eye on this one.
#CancerResearch #Biotech #ClinicalTrials #Oncology

$HOTH Trading sideways here building up for a nice move up. A lot of room to run north from here! Average price target $4.75... Looking bullish heading into next week!

$HOTH A Letter From Our CEO ~ A commitment to patients and their families. Innovation. Responsibility. Integrity.
https://hoththerapeutics.com/letter-from-ceo/

We founded Hoth on the belief that biotech companies must go beyond drug development and marketing – we hold a commitment to the patients and their families to deliver therapeutics that address patient needs. Hoth honors this commitment by selecting innovative therapies for development that will make a difference in the patient treatment experience and improve treatment outcomes. The goal of improving patient quality of life is within our company core and drives our development process. Based on our philosophy, Innovating for Everyone, we believe that all patients deserve the best quality of life possible even while undergoing treatment.

We have endeavored to build Hoth on a foundation of responsible management and ethical conduct. We continue to reinforce this commitment while striving to both serve our patient communities as well as our stakeholders. We understand the importance of our shareholders and investors and work hard to build their confidence in our vision and build long-term value through our clinical development.

We pride ourselves in the strong corporate values that are the backbone of our team. Our employees, management team, board of directors and scientific advisors consistently demonstrate our company values of innovation, responsibility, and integrity. Our company thrives on collaboration to ensure efficient, innovative, and strategic development. We collaborate with academic institutions, expert clinicians, and specialized contract manufacturing organizations to work towards a common vision of improved patient care. Our company goal is to drive cost effective and innovative early phase pharmaceutical development that provides value to pharmaceutical and biopharmaceutical company partners for commercialization and ultimately extend this value to the patients we serve.

Since 2017, our team and company has grown and expanded to execute our goal of bringing innovative solutions to patient communities and long-term value to stakeholders. We keep these goals in mind as we continue our journey of growth and thank you for being a part of it.

Robb Knie
Founder, President & Chief Executive Officer

$HOTH Big News This Week ~ Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-plans-to-submit-expanded-access-application-for-ht-001-to-support-cancer-patients-in-need-302396474.html

Don’t get left holding the bag again

$HOTH Hoth Therapeutics: A game-changer in the fight against unmet medical needs.

💎 Strong Drug Pipeline
💎 Zero Debt
💎 $10 million cash On Hand
💎 $4.75 Average Price Target
💎 No Plans For Any Offering At This Time
💎 Steady News Stream
💎 Game-Changing Potential in Treatment for obesity
and reduced fatty liver disease.
💎 Strong Cancer Treatment Partnership
💎 Low Float ~ O/S 6.9M shares
💎 Partnership with Department of Veterans Affairs

Looking strong in the Pre-market

"The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt."💪

https://ir.hoththerapeutics.com/single-news-releases/?storyId=6941980235753684

$HOTH Undervalued at the current price. 🚀

Way below the potential analyst target of $4.75.

$HOTH Recent Shareholder Update: Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
https://ir.hoththerapeutics.com/single-news-releases/?storyId=6941980235753684

Way undervalued here with a $4.75 Price Target

$HOTH up to $1.14 premarket, broke above the 5min LRC trend line.

$HOTH Nice volume on news today:
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-plans-to-submit-expanded-access-application-for-ht-001-to-support-cancer-patients-in-need-302396474.html

Hoth Therapeutics Acquires New Patent Applications Enhances its Intellectual Property Portfolio.
https://www.contractpharma.com/breaking-news/hoth-therapeutics-acquires-new-patent-applications/

$HOTH

$HOTH News Out! Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-plans-to-submit-expanded-access-application-for-ht-001-to-support-cancer-patients-in-need-302396474.html

$HOTH Hoth Therapeutics: Strong Pipeline & $4.75 Price Target
https://allcapresearch.com/f/hoth-therapeutics-hoth-strong-pipeline-475-price-target?fbclid=IwY2xjawI7A7VleHRuA2FlbQIxMAABHWXoBbxSXA4VQN1BBNet7rD8sMgzp5Gwc-L7z9Yr894OejsxUpLRX1Lg2A_aem_gq-SB3xUXinOsRGDFa534A

50 - 100% potential here next week

$HOTH Many Reasons To Like Hoth Therapeutics Here!

This could be the biotech play of the year. 📈

HOTH....................................https://stockcharts.com/h-sc/ui?s=HOTH
&p=W&b=5&g=0&id=p86431144783

$HOTH Is Flying Under The Radar! 🚨

Current Price = Undervalued. Analyst Average Target = $4.75.

This sleeper stock wont stay quiet for long... 👀

$HOTH has a big opportunity in the obesity market!   Look what all the GLP-1S have done w the market space.   Big things here 

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy Expenditure
Hoth is developing this therapeutic in Partnership with the Department of Veterans Affairs
Key Findings from the Study:

Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.
Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.
Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat storage, including PPAR-?, FASN, and SREBF1, while promoting fat oxidation pathways.
Improved Insulin Sensitivity and Glucose Regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health.
Reduced Fatty Liver Disease – GDNF prevented hepatic steatosis (fat accumulation in the liver), a common obesity-related complication.
NEW YORK, March 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor (GDNF) as a revolutionary treatment for obesity. The study, conducted in GDNF-transgenic (GDNF-tg) models, demonstrated that GDNF significantly reduces fat accumulation, enhances metabolism, and improves insulin sensitivity, even under high-fat diet conditions.


"These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment," said Robb Knie CEO of Hoth Therapeutics. "Unlike traditional weight-loss interventions that primarily focus on appetite suppression or caloric restriction, GDNF directly enhances the body's natural ability to burn fat and increase metabolic efficiency."

Key Findings from the Study:

Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.
Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.
Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat storage, including PPAR-?, FASN, and SREBF1, while promoting fat oxidation pathways.
Improved Insulin Sensitivity and Glucose Regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health.
Reduced Fatty Liver Disease – GDNF prevented hepatic steatosis (fat accumulation in the liver), a common obesity-related complication.
A Paradigm Shift in Obesity Treatment

Obesity is a major global health crisis, affecting over 650 million adults worldwide and contributing to life-threatening conditions such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Current pharmacological treatments often have limited efficacy or undesirable side effects. Hoth Therapeutics' research into GDNF suggests a novel mechanism for weight management that works by enhancing energy metabolism rather than restricting food intake.

"The data suggest that GDNF-based therapies could offer an entirely new approach to obesity treatment—one that activates the body's natural metabolic processes to burn excess fat efficiently," added Robb Knie, CEO Hoth Therapeutics. "This represents a significant advancement over current anti-obesity drugs, which often fail to maintain long-term weight loss."

Next Steps in Development

Hoth Therapeutics is actively exploring multiple pathways for the clinical translation of GDNF-based therapies, including recombinant protein delivery, gene therapy, and small-molecule mimetics that can activate the same metabolic pathways. The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients in need.

For more information on Hoth Therapeutics and its innovative pipeline, please visit www.hoththerapeutics.com

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on thi

HOTH.................................................................a/h

HOTH..........................................................................................p/m

HOTH Regains Nasdaq Compliance! https://www.prnewswire.com/news-releases/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-302359435.html

HOTH price target is $4.75 on average with a STRONG BUY rating according to a new analysis by 4 analysts released today.
It seems like she'll be slowly moving up over time. Thanks for the response.
https://stockanalysis.com/stocks/hoth/forecast/

$2.56 Temporary short killer be back down under $2 soon enough. Be careful with pharmas in this new market environment up and down harsh movements. I would say take what you can on most always the exceptions

+100% move on this PR Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries $HOTH https://t.co/dNvu45yd3A— Life Science Report (@lifesciencerpt) January 8, 2025

RSI is at 93 .....odds are she'll give back some gains based on that.....however, just cause a stock is overbought, doesn't mean it can't get MORE overbought.....lol........Depends on why she ran.....if the reason is good enough, she'll keep going up........

Z

Question: Do you think HOTH will continue to run tomorrow or give back all its gains?

#DDAmanda Video - $HOTH - Gain: +304% Video Analysis - #1 Stock Screener / Scanner



Z

I did. Sideways consolidation @2.50ish for 2 hours now.
Still bullish uptrend

HOTH 100%-Success-on-Phase II-trials-of-their-Cancer Drug, GJ

HOTH, new 52/week high

HOTH: Round-2, if yah grabbed some circa 45-minutes ago!!!

HOTH might get bought by Big Pharma..
IDK this for certain but that's how this "usually" plays out.
No putting out misinformation.

HOTH: Not yet, Homeboy. (I simply spotted THIS one in the Pre-Market today, when it suddenly popped-up at the BOTTOM of Benzinga's nice, short, Pre-Market-Runners, LIST --- an item which then soared near the TOP thereof rapidly.)
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExa2RjN3k2cTdwbThoNzFqaHVwdGk3ZWpzYjVqcWh3czE0MHZpOG44biZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/R51a8oAH7KwbS/giphy.gif
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

so you got a line on the next "HOTH"? Before it catapults.

HOTH: A classic NO-Brainer, Bro!! (And I myself DO qualify in THAT regard --- truth-be-told; heck, see film-clip of ME & my Girl Friend, just yesterday, on the way to school way over here in San Diego,CA!!)


"Stupid is, as stupid DOES, Sweetheart!"
///////////////////////////////////////////////////////////////////////////////////////////////////////

Damn! good one and congrats.

$3.38 +313% Low floater power happy you hung in there on FUBO 

HOTH: I fricken NAILED this suckah!!!!

dang

Awesome run!

$HOTH

Giant news for HOTH.. Congrats.

HOTH: And there it goes!!

hoth.....................https://stockcharts.com/h-sc/ui?s=hoth&p=W&b=5&g=0&id=p86431144783

Yeah, the News is interesting😆 = Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University

Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.


The licensed technology centers on "Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions," a groundbreaking innovation aimed at addressing critical challenges in treating obesity and associated health conditions. This agreement underscores Hoth Therapeutics' commitment to advancing transformative healthcare solutions.

Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.

"We are honored to collaborate with the VA and Emory University to bring this cutting-edge technology to market," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "This partnership represents a significant milestone in our efforts to address obesity and related health conditions with innovative, science-driven solutions. We look forward to advancing this critical work to improve the lives of patients worldwide."

The agreement includes a comprehensive development plan, ensuring the continued progress of this technology from the research phase through commercialization. Hoth Therapeutics plans to leverage its expertise and resources to bring the licensed products to the point of practical application while adhering to rigorous development benchmarks.

This collaboration exemplifies Hoth's dedication to fostering partnerships that advance scientific discoveries into therapeutic solutions. The company remains steadfast in its mission to improve patient outcomes and address unmet medical needs.

Hoth has also entered into an agreement to further protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001. The additional intellectual property expands HT-001's reach to other cancer therapeutics.

About Hoth Therapeutics, Inc.

Nice!😇